TAK-242, a Toll-like receptor 4 antagonist, protects against aldosterone-Induced Cardiac and Renal Injury

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Zhang, Yide ^a   Peng, Weisheng ^b   Ao, Xiang ^b   Dai, Houyong ^a   Yuan, Li ^a   Huang, Xinzhong ^a   Zhou, Qiaoling ^b  

^a NANTONG UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; COLLAGEN TYPE 1; CREATININE; INTERLEUKIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RESATORVID; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; ETHYL 6-(N-(2-CHLORO-4-FLUOROPHENYL)SULFAMOYL)CYCLOHEX-1-ENE-1-CARBOXYLATE; PROTECTIVE AGENT; SULFONAMIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; EPITHELIAL MESENCHYMAL TRANSITION; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY MASS; MALE; NONHUMAN; RAT; UPREGULATION; URINE VOLUME; ACUTE KIDNEY INJURY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; HEART DISEASES; HEMODYNAMICS; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ACUTE KIDNEY INJURY; ALDOSTERONE; ANIMALS; CYTOKINES; HEART DISEASES; HEMODYNAMICS; INFLAMMATION; MALE; PROTECTIVE AGENTS; RATS; RATS, WISTAR; SULFONAMIDES; TOLL-LIKE RECEPTOR 4;

EID: 84953205104     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0142456     Document Type: Article

References (48)

1. Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9: 459-469. doi: 10.1038/nrneph.2013.110
2. Irita J, Okura T, Jotoku M, Nagao T, Enomoto D, et al. (2011) Osteopontin deficiency protects against aldosterone-induced inflammation, oxidative stress, and interstitial fibrosis in the kidney. Am J Physiol Renal Physiol 301: F833-844. doi: 10.1152/ajprenal.00557.2010
3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
4. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, et al. (2004) Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93: 990-996.
5. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, et al. (2003) Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 1021-1026.
6. de las Heras N, Ruiz-Ortega M, Miana M, Ruperez M, Sanz-Rosa D, et al. (2007) Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 25: 629-638.
7. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, et al. (2000) Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219-1227.
8. Rafiq K, Hitomi H, Nakano D, Nishiyama A (2011) Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci 115: 1-7.
9. Zhang YD, Dai HY, Xie HL, Zhou QL, Liu ZH (2013) The role of renal damage on cardiac remodeling in patients with diabetic nephropathy. Clin Nephrol 80: 249-255. doi: 10.5414/CN107875
10. Savoia C, Schiffrin EL (2006) Inflammation in hypertension. Curr Opin Nephrol Hypertens 15: 152-158.
11. Li JJ, Chen JL (2005) Inflammation may be a bridge connecting hypertension and atherosclerosis. Med Hypotheses 64: 925-929.
12. Lee SB, Kalluri R (2010) Mechanistic connection between inflammation and fibrosis. Kidney Int Suppl: S22-26. doi: 10.1038/ki.2010.418
13. Meng XM, Nikolic-Paterson DJ, Lan HY (2014) Inflammatory processes in renal fibrosis. Nat Rev Nephrol 10: 493-503. doi: 10.1038/nrneph.2014.114
14. Doi T, Doi S, Nakashima A, Ueno T, Yokoyama Y, et al. (2014) Mizoribine ameliorates renal injury and hypertension along with the attenuation of renal caspase-1 expression in aldosterone-salt-Treated rats. PLoS One 9: e93513. doi: 10.1371/journal.pone.0093513
15. Frangogiannis NG (2014) The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 11: 255-265. doi: 10.1038/nrcardio.2014.28
16. Tang SC, Yiu WH, Lin M, Lai KN (2015) Diabetic nephropathy and proximal tubular damage. J Ren Nutr 25: 230-233. doi: 10.1053/j.jrn.2014.10.020
17. Stribos EG, van Werkhoven MB, Poppelaars F, van Goor H, Olinga P, et al. (2015) Renal expression of Toll-like receptor 2 and 4: dynamics in human allograft injury and comparison to rodents. Mol Immunol 64: 82-89. doi: 10.1016/j.molimm.2014.11.003
18. Hernanz R, Martinez-Revelles S, Palacios R, Martin A, Cachofeiro V, et al. (2015) Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br J Pharmacol.
19. Summers SA, Steinmetz OM, Ooi JD, Gan PY, O'Sullivan KM, et al. (2010) Toll-like receptor 9 enhances nephritogenic immunity and glomerular leukocyte recruitment, exacerbating experimental crescentic glomerulonephritis. Am J Pathol 177: 2234-2244. doi: 10.2353/ajpath.2010.100153
20. Paulus P, Rupprecht K, Baer P, Obermuller N, Penzkofer D, et al. (2014) The early activation of toll-like receptor (TLR)-3 initiates kidney injury after ischemia and reperfusion. PLoS One 9: e94366. doi: 10. 1371/journal.pone.0094366
21. Moreth K, Frey H, Hubo M, Zeng-Brouwers J, Nastase MV, et al. (2014) Biglycan-Triggered TLR-2-And TLR-4-signaling exacerbates the pathophysiology of ischemic acute kidney injury. Matrix Biol 35: 143-151. doi: 10.1016/j.matbio.2014.01.010
22. Jenke A, Wilk S, Poller W, Eriksson U, Valaperti A, et al. (2013) Adiponectin protects against Toll-like receptor 4-mediated cardiac inflammation and injury. Cardiovasc Res 99: 422-431. doi: 10.1093/cvr/cvt118
23. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, et al. (2013) Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int 33: 398-409. doi: 10.1111/liv.12047
24. Echem C, Bomfim GF, Ceravolo GS, Oliveira MA, Santos-Eichler RA, et al. (2015) Anti-Toll like receptor 4 (TLR4) therapy diminishes cardiac remodeling regardless of changes in blood pressure in spontaneously hypertensive rats (SHR). Int J Cardiol 187: 243-245. doi: 10.1016/j.ijcard.2015.03.190
25. Matsuda S, Umemoto S, Yoshimura K, Itoh S, Murata T, et al. (2015) Angiotensin Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4. J Atheroscler Thromb.
26. Dange RB, Agarwal D, Masson GS, Vila J, Wilson B, et al. (2014) Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res 103: 17-27. doi: 10.1093/cvr/cvu067
27. Eissler R, Schmaderer C, Rusai K, Kuhne L, Sollinger D, et al. (2011) Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res 34: 551-558. doi: 10.1038/hr.2010.270
28. Ha T, Li Y, Hua F, Ma J, Gao X, et al. (2005) Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res 68: 224-234.
29. Sha T, Iizawa Y, Ii M (2011) Combination of imipenem and TAK-242, a Toll-like receptor 4 signal transduction inhibitor, improves survival in a murine model of polymicrobial sepsis. Shock 35: 205-209. doi: 10.1097/SHK.0b013e3181f48942
30. Yao L, Kan EM, Lu J, Hao A, Dheen ST, et al. (2013) Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: role of TLR4 in hypoxic microglia. J Neuroinflammation 10: 23. doi: 10.1186/1742-2094-10-23
31. Clemitson JR, Pratt JR, Frantz S, Sacks S, Samani NJ (2002) Kidney specificity of rat chromosome 1 blood pressure quantitative trait locus region. Hypertension 40: 292-297.
32. Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM (2010) miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 285: 25221-25231. doi: 10.1074/jbc.M110.116137
33. Beg AA (2002) Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 23: 509-512.
34. Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D (2002) Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1. Int J Cardiol 83: 13-21.
35. Jia L, Ma X, Gui B, Ge H, Wang L, et al. (2015) Sorafenib ameliorates renal fibrosis through inhibition of TGF-beta-induced epithelial-mesenchymal transition. PLoS One 10: e0117757. doi: 10.1371/journal. pone.0117757
36. Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, et al. (2012) Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 287: 1478-1488. doi: 10.1074/jbc.M111.279836
37. Sun CY, Chang SC, Wu MS (2012) Uremic toxins induce kidney fibrosis by activating intrarenal reninangiotensin-Aldosterone system associated epithelial-To-mesenchymal transition. PLoS One 7: e34026. doi: 10.1371/journal.pone.0034026
38. Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6: 261-273. doi: 10.1038/nrneph.2010.30
39. Elmarakby AA, Quigley JE, Olearczyk JJ, Sridhar A, Cook AK, et al. (2007) Chemokine receptor 2b inhibition provides renal protection in angiotensin II-salt hypertension. Hypertension 50: 1069-1076.
40. Takeda K, Akira S (2004) TLR signaling pathways. Semin Immunol 16: 3-9.
41. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.
42. Shirali AC, Goldstein DR (2008) Tracking the toll of kidney disease. J Am Soc Nephrol 19: 1444-1450. doi: 10.1681/ASN.2008010123
43. Cohen J (2002) The immunopathogenesis of sepsis. Nature 420: 885-891.
44. Devaraj S, Jialal I, Yun JM, Bremer A (2011) Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism 60: 256-259. doi: 10.1016/j.metabol.2010.01.005
45. Devaraj S, Tobias P, Kasinath BS, Ramsamooj R, Afify A, et al. (2011) Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol 31: 1796-1804. doi: 10.1161/ATVBAHA.111.228924
46. Jialal I, Major AM, Devaraj S (2014) Global Toll-like receptor 4 knockout results in decreased renal inflammation, fibrosis and podocytopathy. J Diabetes Complications 28: 755-761. doi: 10.1016/j. jdiacomp.2014.07.003
47. Garate I, Garcia-Bueno B, Madrigal JL, Caso JR, Alou L, et al. (2014) Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. J Neuroinflammation 11: 8. doi: 10.1186/1742-2094-11-8
48. Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, et al. (2007) Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 571: 231-239.